NCT07920679
Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study title shortened, about 10 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
The proportion of study participants with a Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) score below 8 at Week 24 after administration of K-CAB Tab/K-CAB ODT 25 mg
Timeframe: At Week 24 after enrollment
Sites
1 site in 1 country
- HK inno.NSeoul, South Korea